



## MEDICAL TIPS

### TENEBLU TABLETS

Issue VIII, No. 29, 2022

#### **Effectiveness and safety of teneligliptin added to patients with type 2 diabetes inadequately controlled by oral triple combination therapy: A multicenter, randomized, double-blind, and placebo-controlled study**

*Lee M et al. Diabetes, Obesity & Metabolism 2022; 24(6): 1105-1113.*

- A multicentre, randomized, double-blind, placebo-controlled study was conducted to evaluate the efficacy of teneligliptin added to an existing oral triple combination therapy in inadequately controlled T2DM patients.
- 99 patients with a mean HbA1c of 7.8%, were divided to receive either teneligliptin or placebo for 12 weeks in addition to their existing oral triple combination regimen.
- At the end of 12 weeks the teneligliptin group achieved a significant reduction in HbA1c as compared to the placebo group.
- The safety profile was favourable in both the groups.

**Teneligliptin could be a valid OAD option for the treatment of patients with T2D inadequately controlled with a triple combination of OADs**

